Signatera™ for Bile Cuct Cancer (cholangiocarcinoma)

Signatera™ is setting the standard for MRD testing in biliary tract cancer. Each assay is custom-designed to detect molecular residual disease earlier than standard biomarkers like CA19-9 and CEA, giving you actionable insight to guide post-surgical risk stratification and treatment decisions.

Speak with an expert

SGN_WB_GR_MD_BileDuct_20260206_NAT-8023549_TextImage-02

Identify recurrence sooner

Surveillance ctDNA status outperformed traditional biomarkers

Signatera™-positivity during surveillance was the strongest predictor of relapse-free survival, while CA19-9 and CEA showed no prognostic value.¹

Clinical questions Signatera™ may help answer in biliary cancer

Is Signatera™ for bile duct cancer right for your patients?

First Name *

Last Name *

Email Address *

Phone *

Zip Code *

Country *

I am a *

Company

Comments

Natera Honey Pot

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time. By submitting your information you are agreeing to Natera's terms of use and privacy policy.

References

¹Abdelrahim M et al. Poster #420. Real-world ctDNA analysis in resected Stage I–III biliary tract cancer. Presented at ASCO 2025